Cardiac Mapping System Market

Cardiac Mapping System Market by Product (Electro-anatomical Mapping Systems (3D-Mapping), Electrophysiological Catheters (Contact), and Electromagnetic Mapping System (Non-Contact)), Indication (Atrial Fibrillation, Atrial Flutter, Atrioventricular Nodal Reentry Tachycardia, and Others), End-User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising incidence of cardiac arrhythmias, increasing preference for minimally invasive procedures, and increase in product development activities across the globe.

The cardiac mapping system market is estimated to grow at a CAGR of 8.37% during the forecast period from 2025 to 2032. The rising prevalence of cardiac arrhythmias, like atrial fibrillation and ventricular tachycardia, is fueling the growth of the cardiac mapping system market. These systems are essential for early diagnosis and treatment, offering real-time images of heart electrical activity to prevent serious complications such as stroke and heart failure. Additionally, there is an increasing preference for minimally invasive procedures, such as catheter ablation, which rely heavily on advanced cardiac mapping systems to ensure success. Furthermore, continuous advancements in technology and increased product development activities by key market players are enhancing the capabilities of cardiac mapping systems, making them more efficient, user-friendly, and widely accessible. Together, these factors are expected to increase the demand for cardiac mapping systems across the globe during the forecast period from 2025 to 2032.

Cardiac Mapping System Market Dynamics:

According to the World Heart Federation (2024), globally, approximately 60 million population are affected by atrial fibrillation which is one of the most common types of irregular heartbeat, or arrhythmia. It can increase the risk of blood clots, heart failure, and stroke. Additionally, as per the same source people with atrial fibrillation are 5X times more likely to suffer a stroke. Furthermore, according to the recent data and stats provided by the Australian Institute of Health and Welfare (2024), in 2021, more than 500,000 population were affected by atrial fibrillation.

According to recent data provided by the British Heart Foundation (2024), globally, around 56 million women and 45 million men are stroke survivors. It's estimated that at least 13 million people worldwide live with congenital heart disease, with potentially millions more undiagnosed.

Cardiac mapping systems are essential in the management of atrial fibrillation because they provide detailed, real-time insights into the electrical activity of the heart, enabling precise identification of abnormal pathways that cause irregular heartbeats. This accuracy is crucial for guiding catheter ablation procedures, which are increasingly preferred as a minimally invasive treatment for atrial fibrillation. The ability of cardiac mapping systems to improve the success rates of these procedures and reduce the risk of recurrence makes them highly valuable in modern cardiology. Additionally, ongoing advancements in mapping technology, such as the development of more sophisticated 3D mapping systems, are further enhancing the effectiveness of atrial fibrillation treatment, thereby boosting the demand for cardiac mapping systems across the globe.

Furthermore, the significance of key market players involved in strategic product development activities is further boosting the overall market of cardiac mapping systems. For instance, in January 2022, Abbott received the U.S. FDA clearance for its new cardiac mapping system, the EnSite™ X EP System with EnSite Omnipolar Technology (OT), which was designed to improve how doctors treat abnormal heart rhythms.

Thus, the factors mentioned above are likely to boost the market of cardiac mapping systems during the forecasted period.

However, the complications and risks associated with contact cardiac mapping systems such as bleeding, infection, damage to the heart tissue, and exposure to radiation which can pose long-term health risks to patients, and stringent regulatory concerns may hinder the future market of cardiac mapping systems.

Cardiac Mapping System Market Segment Analysis:

Cardiac Mapping System Market by Product (Electro-anatomical Mapping Systems (3D-Mapping), Electrophysiological Catheters (Contact), and Electromagnetic Mapping (Non-Contact)), Indication (Atrial Fibrillation, Atrial Flutter, AVNRT, and Others), End-User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product segment of the cardiac mapping system market, an electro-anatomical mapping system (3D mapping) is expected to have a revenue share in the year 2024. These systems create highly detailed, three-dimensional representations of the heart's electrical activity, allowing for precise identification of arrhythmia sources and their exact locations within the heart tissue. This level of detail is particularly beneficial for guiding catheter ablation procedures, where accuracy is crucial for targeting and eliminating abnormal electrical pathways while minimizing damage to surrounding healthy tissue.

The ability of 3D mapping systems to integrate with other imaging modalities, such as MRI and CT scans, further enhances their utility, providing a comprehensive view of both the heart’s anatomy and its electrical function. This integration leads to improved procedural outcomes, reduced operation times, and lower recurrence rates of arrhythmias, which is a key driver for their adoption in clinical practice. Additionally, the non-fluoroscopic nature of many 3D mapping systems reduces radiation exposure for both patients and clinicians, addressing a significant concern associated with traditional mapping techniques. 

Moreover, continuous innovations in electro-anatomical mapping technology, such as improvements in mapping accuracy, ease of use, and compatibility with various catheters and imaging systems, are expanding the market’s potential even further. For instance, in May 2024, Biosense Webster, Inc., part of Johnson & Johnson MedTech, launched a new version of its CARTO™ 3 Electro-Anatomical Mapping System. The updated system, used in cardiac ablation procedures, featured new modules, including the CARTO ELEVATE™ Module and CARTOSOUND™ FAM Module, designed to enhance efficiency, reproducibility, and accuracy for electrophysiologists treating atrial fibrillation (AFib) and other arrhythmias. Thus, these advancements make electro-anatomical systems an attractive option for a broader range of healthcare settings, from large tertiary care centers to smaller, specialized clinics, contributing to the overall expansion of the cardiac mapping system market. Thus, owing to the above-mentioned factors the segment is expected to generate considerable revenue thereby pushing the overall growth of the global cardiac mapping system market during the forecast period.

North America is expected to dominate the overall cardiac mapping system market:

Among all the regions, North America is expected to hold the largest share of the cardiac mapping system market in 2024. This dominance is driven by the rising cases of cardiac arrhythmias, like atrial fibrillation and ventricular tachycardia, increasing adoption of minimally invasive procedures, increased healthcare initiatives by government and key market players involved in strategic product development activities, and the heightened awareness among the population across the region are expected to boost the market during the forecast period across the region.

According to recent data from the Centers for Disease Control and Prevention (2024), approximately 4.9% of adults were diagnosed with coronary heart disease in 2022. Furthermore, by 2023, an estimated 12.1 million individuals in the United States were projected to have atrial fibrillation. Additionally, each year, over 795,000 people in the U.S. experience a stroke, with around 610,000 of these being first-time strokes. Thus, atrial fibrillation, stroke, and coronary heart disease are key drivers of the growth of the cardiac mapping systems market. Atrial fibrillation, the most common arrhythmia, increases the risk of stroke and heart failure, requiring precise heart mapping for effective treatments like catheter ablation. Cardiac mapping systems provide crucial high-resolution images for diagnosing and managing these conditions, particularly in stroke prevention and coronary heart disease, where arrhythmias are common. As these cardiovascular issues rise, so does the demand for advanced cardiac mapping technologies across the region. Further, growing product development initiatives by key market players for the treatment of cardiac mapping systems in the United States are expected to drive the market growth of cardiac mapping systems. For instance, in April 2024, Medtronic PLC announced positive interim results from the Sphere-360™ clinical trial, demonstrating safety and efficacy for its investigational single-shot mapping and ablation catheter using pulsed-field energy to treat paroxysmal atrial fibrillation (AFib). Thus, all the above-mentioned factors are anticipated to propel the market for cardiac mapping systems in North America during the forecast period from 2025 to 2032.

Cardiac Mapping System Market Key Players:

Some of the key market players operating in the cardiac mapping system market include Medtronic PLC, Abbott, Biosense Webster, Inc. (Johnson & Johnson MedTech), Boston Scientific Corporation, Corify Care, Galvanize Therapeutics, Inc., Ablacon, Inc., Acutus Medical, Inc., Field Medical, Inc., CardioNXT, Inc., Siemens Healthineers, Lepu Medical, Catheter Robotics, Inc., Koninklijke Philips N.V., Stereotaxis, Inc., Biotronik SE & Co. KG, CoreMap, Inc., Nihon Kohden Corporation, EP MedSystems, Inc., Norav Medical, and others.

Recent Developmental Activities in the Cardiac Mapping System Market:

• In July 2024, Corify Care received the CE Mark Certification for ACORYS MAPPING SYSTEM. The ACORYS MAPPING SYSTEM is the fastest non-invasive cardiac mapping technology on the market.
• In March 2023, Galvanize Therapeutics, Inc. announced the first human investigational use of its QuickShot™ Pulsed Electric Field (PEF) ablation catheter in the QuickShot PEF-AF clinical study. QuickShot offers mapping through a marketed electroanatomical mapping system and ablation in a single catheter.

Key Takeaways From the Cardiac Mapping System Market Report Study:

• Market size analysis for current cardiac mapping system size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the cardiac mapping system market.
• Various opportunities available for the other competitors in the cardiac mapping system market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current cardiac mapping system market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for cardiac mapping system market growth in the coming future?

Target Audience Who Can be Benefited From This Cardiac Mapping System Market Report Study:

• Cardiac mapping system product providers
• Research organizations and consulting companies 
• Cardiac mapping system-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in cardiac mapping system 
• Various end-users who want to know more about the cardiac mapping system market and the latest technological developments in the cardiac mapping system market.  

Frequently Asked Questions for the Cardiac Mapping System Market:

1. What are cardiac mapping systems?

• A cardiac mapping system is a diagnostic tool used to create detailed, three-dimensional maps of the heart's electrical activity. It helps identify and visualize abnormal electrical signals and pathways, enabling precise diagnosis and treatment of arrhythmias. This system often integrates with other technologies to guide procedures like catheter ablation and optimize patient outcomes.

2. What is the market for cardiac mapping systems?

• The cardiac mapping system market is estimated to grow at a CAGR of 8.37% during the forecast period from 2025 to 2032. 

3. What are the drivers for the cardiac mapping system market?

• The rising prevalence of cardiac arrhythmias, like atrial fibrillation and ventricular tachycardia, is fueling the growth of the cardiac mapping system market. These systems are essential for early diagnosis and treatment, offering real-time images of heart electrical activity to prevent serious complications such as stroke and heart failure. Additionally, there is an increasing preference for minimally invasive procedures, such as catheter ablation, which rely heavily on advanced cardiac mapping systems to ensure success. Furthermore, continuous advancements in technology and increased product development activities by key market players are enhancing the capabilities of cardiac mapping systems, making them more efficient, user-friendly, and widely accessible. Together, these factors are expected to increase the demand for cardiac mapping systems across the globe during the forecast period from 2025 to 2032.

4. Who are the key players operating in the cardiac mapping system market?

• Some of the key market players operating in the Cardiac Mapping System market include Medtronic PLC, Abbott, Biosense Webster, Inc. (Johnson & Johnson MedTech), Boston Scientific Corporation, Corify Care, Galvanize Therapeutics, Inc., Ablacon, Inc., Acutus Medical, Inc., Field Medical, Inc., CardioNXT, Inc., Siemens Healthineers, Lepu Medical, Catheter Robotics, Inc., Koninklijke Philips N.V., Stereotaxis, Inc., Biotronik SE & Co. KG, CoreMap, Inc., Nihon Kohden Corporation, EP MedSystems, Inc., Norav Medical, and others.

5. Which region has the highest share in the cardiac mapping system market?

• Among all the regions, North America is expected to hold the largest share of the cardiac mapping system market in 2024. This dominance is driven by the rising cases of cardiac arrhythmias, like atrial fibrillation and ventricular tachycardia, increasing adoption of minimally invasive procedures, increased healthcare initiatives by government and key market players involved in strategic product development activities, and the heightened awareness among the population across the region are expected to boost the market during the forecast period across the region.